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Abstract
Depression screening is recommended for all pregnant veterans; however, little is known on
how often symptomatic women receive care, how depression treatment presents in practice,
and whether women veterans are utilizing treatment during the appreciable perinatal period.
Our sample included 142 pregnant veterans from 15 Veterans Health Administration (VA)
medical facilities with Edinburgh Postnatal Depression Scale (EPDS) scores ≥10.
Sociodemographic characteristics, military service, health utilization, and pregnancy related
factors were collected as part of a telephone survey. A majority of our sample (70%) had 1 or
more mental health visits or antidepressant prescriptions during pregnancy. Women with a
history of depression had more mental health visits and a higher percentage of antidepressant
use before and during pregnancy than women without a history of depression. Pregnant
women veterans without a history of depression may be less likely to receive care for
depression during pregnancy. However, the majority of our veterans showing depression
symptoms prenatally had at least one mental health visit or an antidepressant medication fill
during their pregnancy window, suggesting that mental health care is readily available for
women veterans.
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Background
Depression is common during the prenatal period among women veterans [1]. Women
veterans are more likely to experience combat-related trauma and post-deployment stressors,
and in general have higher rates of depression, compared to the general population [2]. A
recent prospective study identified depression symptoms in nearly 30% of pregnant veterans
[3]. Despite high rates of depression, there is little understanding of how pregnant veterans
manage their mental healthcare during pregnancy, especially important because the perinatal
time marks a distinct period when women encounter their providers on a regular basis, offering
unique opportunities for screening and treatment for depression [4].
Because women remain a numerical minority in the Veterans Health Administration (VA),
VA medical facilities do not provide onsite maternity care. Rather, maternity care for veterans
is provided by non-VA obstetricians and reimbursed by the VA. The VA recommends
depression screening for all pregnant veterans [5], however, there is a paucity of research
regarding the frequency or quality of depression treatment during pregnancy. Previous studies
suggest that while receiving prenatal care from non-VA providers, a substantial proportion of
veterans concurrently receive mental health care within the VA [1, 6]. Coordination of care
between non-VA and VA providers is an important aspect of maternity care for veterans. VA
guidelines state that information sharing, “particularly in the area of medication management
and monitoring for medications that have teratogenic effects,” is “critical to patient safety” [5].
Coordination of medication risk discussions between the patient, her mental health provider,
and her obstetrician has previously been shown to contribute to greater depression treatment
during the perinatal period [7, 10, 20].
Psychotherapy has been shown to be an effective treatment strategy for pregnant women
with depression [8, 9]. However, therapy brings its own challenges, among them patient
barriers such as cost, travel difficulties, and time constraints [9], as well as systematic barriers
such as lack of provider training, limited access to providers, and absence of standardized
screening and referral processes [10].
To date, few studies have examined pregnant veterans’ use of antidepressants. The preva-
lence rate of antidepressant use during pregnancy has been estimated to be near 5% in the
general population [11, 12], with some point estimates placing antidepressant use at any time
during pregnancy close to 13% [13]. Little is known about the rates of antidepressant use among
pregnant veterans; however, a previous study reported nearly 90% of the sample of female
veterans of childbearing age had used any prescription medication within the past year [14].
Antidepressant use during pregnancy is not without risk, with associations between antidepres-
sant use and miscarriage, low birthweight, preterm birth, and the risk for complications in
newborns such as irritability, tachypnea, hypoglycemia, and temperature instability in the days
following birth [9, 15]. However, the risks of untreated maternal depression include behavior
problems and cognitive delays in infants, comprised care giving practices, reduced rates of
breastfeeding, maternal sleep problems, and greater suicidal ideation compared to women
without depressive symptoms [16, 17]. Both the VA and the American College of Obstetricians
and Gynecologists (ACOG) recommend risk/benefit discussions between a patient and her
provider regarding continuing or starting a functional antidepressant medication during preg-
nancy [15, 18, 19]; however, rates as low as 24% have been reported for discussions between
reproductive age female veterans and their providers about medication risks [14]. These
challenges of available treatment options and the overall low adherence rate to treatment among
depressed pregnant and postpartum women [20] have yet to be studied among veterans.
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Using a mixed-methods approach, our objective was to evaluate the rate of mental health
care treatment utilization during pregnancy and to understand the experience and management
of depression in a sample of pregnant veterans. We identify differences in treatment utilization
during pregnancy among women who report past diagnoses of depression compared to those
with no past diagnosis. Additionally, we explore the decisions women make regarding
antidepressant medication use during pregnancy and the extent to which pregnant veterans
discuss medication risk counseling with their VA and/or obstetrical providers.
Methods
Study Design, Data Source, and Study Sample
Participants were identified at 15 VA sites across the US as part of the Center for Maternal and
Infant Outcomes Research in Translation (COMFORT) study [3, 21]. COMFORT was ap-
proved by the Veterans Administration Central Institutional Review Board (CIRB) and was
given a waiver of consent by the CIRB so that signed consent forms were not required from
participants; however, verbal informed consent was obtained from all individual participants
included in the study. Pregnant veterans were identified by the veteran’s VA provider. To
utilize maternity care benefits, women veterans must have a visit with their VA provider to
confirm their pregnancies prior to obtaining maternity care from an accredited prenatal
provider [5]. All veterans confirmed to be pregnant were mailed recruitment packets that
invited the veteran to call a toll-free number to receive further information. Additionally,
research team members followed up the mailings with telephone calls to potential participants.
Two telephone surveys were scheduled with pregnant veterans who agreed to participate; the
first during the second or third trimester (around 20–24 weeks of gestation) and a second
within three months of delivery.
Participants were reimbursed $25 for each survey. Enrollment rates were roughly 40%; of
the 1410 eligible women who were sent invitation letters, 562 had agreed to participate at the
time of this analysis. Quantitative study data were collected and managed using REDCap
(Research Electronic Data Capture), a secure, web-based application designed to support data
capture for research studies [22]. Additionally, electronic health record (EHR) data on date of
birth, service-connected disability status, past medical diagnoses, and healthcare utilization
during pregnancy were obtained on participants from VA Corporate Data Warehouse (CDW)
administrative data. The CDW is a repository of data updated nightly from the VA electronic
medical records system for operations and research use [23].
Our sample included 142 participants enrolled within the first two years of the study (January
28, 2016 – February 6, 2018) and scoring ≥10 on a prenatal Edinburgh Postnatal Depression
Scale (EPDS); we were able to match 135 (95%) participants to their EHR within the VA CDW.
Of those missing CDW data, the majority (n = 5, 71%) did not provide their social security
number or only provided the last 4 digits, preventing identification in the CDW data. The
remaining participants (n = 2) could not be matched with a social security number in the CDW.
Definition of Quantitative Outcomes
Healthcare utilization was examined through mental health visits and antidepressant use, both
as recorded in VA EHR data and self-reported in the prenatal COMFORT survey. We
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examined healthcare utilization in two time-periods: pre-pregnancy and pregnancy. We defined
pregnancy as 280 days prior to the newborn date of birth (available for 59% of our sample) or
estimated delivery date (for the remaining 41% of our sample), as done in previous analyses
[24, 25]. Pre-pregnancy was considered prior to the start of the pregnancy time period, defined
as 280 to 560 days prior to delivery or estimated due date (newborn date of birth-280 days)-
280 days) (Fig. 1). This gave us comparable time periods to examine healthcare utilization in
our sample prior to and during pregnancy.
To identify mental health care visits, we utilized VA mental health stop codes, indicators in
the EHR that flag the clinical group responsible for an outpatient encounter (Online Resource
A) [26]. We also obtained information on receipt of an antidepressant medication, where a 30-
day fill prescribed at any point during our pre-pregnancy or pregnancy windows was consid-
ered receipt of a prescription antidepressant. We opted to include only antidepressant prescrip-
tions because we specifically asked about antidepressant use in our survey and used the EPDS
to determine depression symptomology. Our definition of antidepressants included selective
serotonin reuptake inhibitors (SSRI), serotonin–norepinephrine reuptake inhibitors (SNRI),
tricyclic antidepressants (TCA), monoamine oxidase inhibitors (MAOI), noradrenergic and
specific serotonergic antidepressants (NASSA), norepinephrine-dopamine reuptake inhibitors
(NDRI), bupropion, selective serotonin reuptake enhancers (SSRE), tianeptine,
norepinephrine-dopamine disinhibitors (NDDI), and agomelatine (Online Resource B). We
created an additional variable, “Any VAMental Health Care during Pregnancy” defined as one
or more mental health visits during pregnancy or any receipt of an antidepressant prescription.
Additionally, we examined self-reported mental health care utilization using responses from
the prenatal survey. Participants were asked about antidepressant use with the following
questions: “Before this recent pregnancy, had you ever been prescribed anti-depressants?”
immediately followed by “Currently, are you taking any medications for mental health
conditions?”. To identify visits with a mental health provider, participants were asked: “At
Fig. 1 Time Periods of Mental Health Care/Antidepressant Prescription Identification from VA Electronic Health
Records
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the time you found out you were pregnant were you seeing a mental health provider?” and
“During this pregnancy will you continue to see a mental health provider?”
Demographic, Military, Health-Related, and Pregnancy Factors
We selected potential correlates of depression care utilization during pregnancy based on
previous literature, including history of depression [27], as well as data available from the
COMFORT telephone survey. The telephone survey collected information including
sociodemographics, military service, health status, healthcare utilization, social support, and
pregnancy related factors. Participants were asked if they had ever been diagnosed with
depression. A 10-item Edinburgh Postnatal Depression Scale (EPDS) was also administered
[28], with a cutoff of 10 used to define present depression symptoms [29] and a cutoff of 13
used to suggest probable major depression [30]. Multiple times during the interview, partic-
ipants were reminded that they could refuse further participation in the study or refuse to
answer specific questions. Participants with affirmative responses to the self-harm question of
the EPDS were directed to further clinical follow-up.
Data used in this analysis included demographics (race/ethnicity, marital status, and
employment status), military characteristics (deployment history and history of military sexual
trauma (MST), adapted from the VA’s universal MST screening questions and described in
previous literature [31]), as well as self-reported past mental health diagnoses from the
COMFORT survey. From the EHR, past depression diagnoses were identified as ever being
present by the following ICD-9 and ICD-10 diagnosis codes: ICD-9: 293.83, 296.2, 296.3,
296.90, 298.0, 300.4, 309.0, 309.1, 311; ICD-10: F32, F33, F34, F39. To examine the
reliability and validity of self-reported depression diagnoses in this sample of veterans, we
performed a reliability analysis using Cronbach’s α and calculated sensitivity, specificity, and
positive predictive values to compare to EHR variables for the same diagnoses. We found
sensitivity, specificity, and positive predictive values rates of 0.90, 0.42, and 0.77, respectively,
with most discordant cases for women self-reporting the condition when it was absent in the
EHR (data not shown). Age, OEF/OIF status, and service-connected status were also obtained
from EHR data. OEF/OIF status included any veteran who served in any of those specific
military tours; service-connected disability status was determined by the Veteran Benefits
Administration and measured as a percentage from 0% to 100%, where 0% is the lowest level
of disability and is different from not having a disability [32]; here dichotomized as presence of
service-connected disability percentage of yes (>0%) or no as in previous analyses [24].
Qualitative Methods
Prior to the start of recruitment, we developed a semi-structured interview guide with questions
related to the experiences of veterans regarding depression management and other mental
health care during pregnancy (Online Resource C). All enrolled veterans participated in the
semi-structured interview. We selected a purposive sample of 42 interviews from participants
with a prenatal EPDS≥10 in which medication management or mental health care were
discussed specifically; these interviews were selected from all interviews with pregnant
veterans showing depressive symptoms.
The open-ended responses of the interview were digitally recorded to capture verbatim
content and were professionally transcribed for this analysis. Interview notes and recordings
were linked by an unidentifiable participant code.
Psychiatric Quarterly
Analysis
Quantitative Analysis
Descriptive statistics, including means, standard deviations, and ranges for continuous vari-
ables, and frequencies for categorical variables, were calculated and presented.
To examine correlates of any VA mental health care during pregnancy, we conducted
bivariate analyses of variables of interest by our derived mental health care variable of one or
more mental health visits during pregnancy or any receipt of an antidepressant prescription.
Chi-squared tests and relative risks with 95% confidence intervals were calculated.
As we additionally sought to learn more about how women veterans treated and managed
their depression symptoms during pregnancy, we then compared demographic, military, and
mental health characteristics by women who reported having been diagnosed with depression
prior to pregnancy versus those who reported no past diagnosis. We used chi-squared tests to
examine differences in categorical factors and Student’s t test to examine mean differences in
continuous factors.
We also ran sensitivity analyses to test the reliability of our 280-day pregnancy window. We
calculated estimated gestational age at delivery in our sample, using the difference between the
date of the prenatal COMFORT interview and self-reported gestational age at that interview to
set a “time zero”. We then calculated the difference between “time zero” and delivery date or
estimated due date. Our average estimated gestational age at delivery was 275.25 days (±
standard deviation of 10.44) with a median and mode of 280 days. Our shortest estimated
gestational period was 203 days; our longest estimated gestational period was 296 days. Given
our minimum and maximum estimated gestational window of 203 days and 296 days, we reran
our calculations of mental health visits and antidepressant prescriptions for pre-pregnancy and
pregnancy windows of 200 and 300 days, respectively (Appendices D & E).
All quantitative analyses were conducted in SAS version 9.2 (SAS Institute, Inc., Cary,
North Carolina).
Qualitative Analysis
We utilized a phenomenological approach to understand how pregnant veterans man-
aged their depression symptoms and mental health care during pregnancy. Phenome-
nological approaches are used to understand situational experiences viewed through
the personal perceptions of participants [33, 34], requiring the researchers to consider
the analysis without preconceived ideas or beliefs about the experiences of the
participants [35]. Guided by this approach, we conducted an exploratory, inductive
analysis similar to methods from previous work [36]. This type of analysis is well-
suited for our semi-structured interview data focusing on pregnancy, where we
interpreted participant responses through an iterative process [33, 34].
We used open coding, where one main coder (ARKD) read participant transcripts line-
by-line, forming initial notes and definitions and then objectively organized personal
narratives into similar experiences, grouping by phrase and keywords. An additional
coder (KM) reviewed these initial codes for clarity and qualitative accuracy. Next, we
interpreted and refined the experiences shared by pregnant veterans and worked to
understand the connections between emergent themes and their descriptions of how
these experiences are shaped. Findings were organized by clusters of superordinate and
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subthemes in a coherent order, retranslated into a narrative account, and considered in
relation to quantitative results. Qualitative analysis was managed in ATLAS.ti version
8.2.30 (Scientific Software GmbH, Berlin, Germany).
Results
Quantitative Results
Women in our sample were on average 31.4 years of age (± 4.5), married (50.7%), white
(52.1%), and deployed in the past (57.7%). Prenatal EPDS scores averaged 14.7 (± 4.0)
(Table 1). Overall, the number of mental health visits increased slightly from the pre-
pregnancy to pregnancy time periods, from 5.3 visits in the 280 days prior to pregnancy, to
6.1 visits during the 280-day pregnancy window (Wilcoxon signed-rank test p = 0.18).
Antidepressant use decreased from 40.1% in pre-pregnancy to 37.0% of our sample having
received a similar prescription during pregnancy (McNemar’s test for paired samples p = 0.21).
A majority of our sample (69.7%) had at least 1 mental health visit or antidepressant
prescription during pregnancy (Table 1). Past treatment for military sexual trauma (MST) (χ2
Table 1 Participant Characteristics (n = 142)
COMFORT Survey Data
Total
Age at Prenatal Interview (Mean ± SD, Range) 31.4 ± 4.5
(22.4–41.7)
Married (N, %) 72 (50.7)
Race: White (N, %) 74 (52.1)
Hispanic or Latino/Latina (N, %) 22 (15.5)
Past Deployment (N, %) 82 (57.7)
OEF/OIF (N, %) 134 (94.4)
Prenatal EPDS (Mean ± SD, Range) 14.7 ± 4.0
(10.0–26.0)
Symptoms of Probable Major Depression, EPDS≥13 (N, %) 90 (63.4)
Weeks Pregnant at Prenatal Interview (Mean ± SD, Range) 23.0 ± 5.3
(4.4–39.1)
Care Utilization from VA CDW Electronic Health Record*
Mental Health visits, mean ± SD (range)
Pre-pregnancy 5.3 ± 9.1
(0–45)
Pregnancy 6.1 ± 9.4
(0–54)
Any Mental Health visits, n (%)
Pre-pregnancy 79 (55.6)
Pregnancy 91 (64.1)
Antidepressant Prescription, n (%)
Pre-pregnancy 57 (40.1)
Pregnancy 50 (35.2)
Any VA Mental Health Care during Pregnancy (1+ mental health visit or antidepressant
prescription in VA CDW EHR) (N, %)
99 (69.7)
CDW: Corporate Data Warehouse; EPDS: Edinburgh Postnatal Depression Scale; OEF/OIF: Operation
Enduring Freedom/Operation Iraqi Freedom; VA: Veterans Affairs
Time periods calculated as Pre-pregnancy= (Newborn date of birth-280)-280; Pregnancy=Newborn date of birth-280
*n = 7 participants were missing CDW data
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p = 0.002) and drug abuse or alcoholism (χ2 p = 0.004), self-reported diagnosis of depression
(χ2 p = 0.0002), PTSD (χ2 p = 0.002), mood disorder (χ2 p = 0.009), and bipolar disorder
(Fisher’s Exact Test p = 0.02), past use of antidepressants (χ2 p < .0001), and established care
with a VA mental health provider prior to pregnancy (χ2 p < .0001) were significantly
associated with at least 1 mental health visit or antidepressant prescription during pregnancy.
Employment was associated with a decreased likelihood of a mental health visit or antide-
pressant prescription during pregnancy (χ2 p = 0.03) (Table 2).
A large proportion of our sample (81.7%) reported a past diagnosis of depression. Those
reporting a history of depression were statistically more likely to score a prenatal EPDS≥13,
suggestive of major depressive symptoms (68% vs. 42%, p = 0.01). Women reporting no
history of depression were more likely to be employed (54% vs. 32%, p = 0.04), less likely to
report treatment for military sexual trauma (19% vs. 43%, p = 0.02), and less likely to report
past diagnoses of PTSD, and bipolar, mood, and anxiety disorders (all p < 0.05) (Table 3).
Care utilization was higher in women with a self-reported history of depression, with a
greater number of mental health visits before and during pregnancy and a higher percentage of
antidepressant use during these same time periods, with 75.9% of women with a history of
depression having some VA mental health care during pregnancy, compared to only 42.3% of
women with no history of depression (p < 0.001) (Table 3; Figs. 2 and 3). This corresponded to
women with a self-reported history of depression being 1.8 times more likely to receive at least
one VA mental health visit or antidepressant prescription during pregnancy than women
without a history of depression (data not shown; relative risk = 1.8, 95% confidence interval =
1.1–2.8).
Our sensitivity results indicated that the proportion of our sample with CDW data (n = 135)
who had mental health visits and/or antidepressant prescriptions varied depending on the
pregnancy window we used (200-days, 280-days, or 300-days). The number of mental health
visits increased as time windows were broadened. Receipt of an antidepressant prescription
was present in 21.5% of women when examining a 200-day pregnancy window; when that
window was expanded to 280-days and 300-days, 37% and 40% of women had received an
antidepressant prescription, respectively. Women receiving at least one VA mental health visit
Table 2 Factors Significantly Associated with Any VA Mental Health Care during Pregnancy* (n = 135)
Χ2, p value Relative Risk Lower
95% CI
Upper
95% CI
Employed vs. Unemployed/Homemaker/Student/Other 4.99, 0.03 0.41 0.19 0.91
Treatment for Military Sexual Trauma (Yes vs. No) 9.90, 0.002 4.34 1.66 11.35
Ever Treatment for Drug Abuse or Alcoholism (Yes vs. No) 8.54, 0.004 – – –
Ever Depression Diagnosis (Yes vs. No) 13.50, 0.0002 5.09 2.03 12.74
Ever PTSD Diagnosis (Yes vs. No) 9.83, 0.002 3.45 1.56 7.62
Ever Mood Disorder Diagnosis (Yes vs. No) 6.90, 0.009 4.78 1.36 16.81
Ever Bipolar Disorder Diagnosis (Yes vs. No) 5.68, 0.01** – – –
Ever Antidepressant Prescription Prior to Pregnancy (Yes vs. No) 17.43, <.0001 6.36 2.51 16.12
Plan to See VA MH Provider during Pregnancy (Yes vs. No) 34.43, <.0001 35.44 7.44 168.73
*1+ mental health visit or antidepressant prescription in VA CDW EHR
**Fisher’s Exact Test for small cell sizes
***No risk estimate computed for Ever Treatment for Drug Abuse or Alcoholism or Ever Bipolar Disorder
Diagnosis due to no self-report of either past condition in the “no VA care during pregnancy” group
CI = confidence interval; PTSD= post-traumatic stress disorder; VA MH=Veterans Affairs Mental Health; n = 7
participants were missing CDW data
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or antidepressant prescription increased slightly when comparing our 200- and 280-day
windows (63.7% vs. 73.3%) but remained the same when comparing 280-day and 300-day
windows (both 73.3%) (Online Resource E).
Qualitative Results
We identified themes that captured the major concepts surrounding medication use during
pregnancy, including themes relevant to mental health medication risk discussions with
providers, use of mental health medications during pregnancy, and discontinuation of mental
health medications during pregnancy (Table 4).
Table 3 Participant Characteristics by Self-Reported Past Depression Diagnosis (n = 142)
Characteristic No History
of Depression
(N = 26)
History
of Depression
(N = 116)
P value
Probable Symptoms of MDD (Prenatal EPDS ≥13) (N, %) 11 (42.3) 79 (68.1) 0.01
First Pregnancy (N, %) 10 (38.5) 32 (27.6) 0.27
Current Employment Status (N, %)
Employed 14 (53.8) 37 (31.9) 0.04
Unemployed/Homemaker/Student/Other 12 (46.2) 79 (68.1)
Service-Connected Status (N, %) 22 (84.6) 103 (88.8) 0.39*
Ever Counseling/Treatment for Military Sexual Trauma (N, %) 5 (19.2) 50 (43.1) 0.02
Ever received medical treatment for drug abuse or alcoholism (N, %) 1 (3.8) 20 (17.2) 0.12*
Self-Reported Mental Health Diagnoses, Ever Diagnosed (N, %)
Bipolar Disorder 0 (0.0) 16 (13.8) 0.04*
Other Mood Disorder 0 (0.0) 35 (30.2) 0.001
Anxiety Disorder 8 (30.8) 88 (75.9) <.0001
PTSD 9 (34.6) 79 (68.1) 0.002
Schizophrenia 0 (0.0) 1 (0.9) 0.99
ADHD or ADD 0 (0.0) 13 (11.2) 0.13*
Eating Disorder 0 (0.0) 10 (8.6) 0.21*
Self-Reported Ever Diagnosis of Any Mental Health Condition** (N, %) 14 (53.8) 116 (100.0) <.0001*
Self-Reported Ever Diagnosis of Any Mental Health Condition**,
excluding depression (N, %)
14 (53.8) 94 (81.0) 0.003
Care Utilization
Seeing MH provider when found out about pregnancy, self-reported (N, %) 7 (26.9) 62 (53.4) 0.03
Planned to see MH provider during pregnancy, self-reported (N, %) 7 (26.9) 68 (58.6) 0.36
Any VA Mental Health Visits Pre-pregnancy (N, %) 7 (26.9) 72 (62.0) 0.0006
Any VA Mental Health Visits during 280-Day Pregnancy Window (N, %) 11 (42.3) 80 (69.0) 0.006
VA Mental Health Visits during 280-Day Pregnancy Window
(Mean ± SD, Range)
2.7 ± 4.7
(0–18)
6.9 ± 10.1
(0–54)
0.003*
Ever Prescribed Anti-Depressants, self-reported (N, %) 10 (38.5) 107 (92.2) <.0001*
Mental health medication use at the time of prenatal interview, self-reported
(N, %)
0 (0.0) 22 (19.0) 0.02*
VA Antidepressant Prescription Pre-pregnancy (N, %) 6 (23.1) 51 (44.0) 0.04
VA Antidepressant Prescription during 280-Day Pregnancy Window (N, %) 3 (11.5) 47 (40.5) 0.004
Any VA Mental Health Care during Pregnancy (1+ mental health visit or
antidepressant prescription in VA CDW EHR) (N, %)
11 (42.3) 88 (75.9) 0.0002
*P value from Fisher’s exact test for categorical variables; Satterthwaite test for unequal variances for continuous
variables. **Any mental health condition variable includes self-reported ever diagnosis of any of the following:
depression, anxiety, PTSD, mood disorder, ADHD/ADD, bipolar disorder, schizophrenia, eating disorder
Time periods: Pre-pregnancy = (Newborn date of birth-280)-280; Pregnancy = Newborn date of birth-280
n = 7 participants were missing CDW data
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“Once I knew, I stopped” Many women reported discontinuing their medications when they
found out they were pregnant. As one woman put it: “Once I knew, I stopped taking
everything…I just went off, completely off of everything, everything.” One woman who had
a planned pregnancy noted that she was trying to “do better as far as managing (her
depression)” to “prevent” her from going back on medication while pregnant. Another
woman stated that she “kind of quit taking” her antidepressants, but later informed her mental
health provider and came up with alternative treatment plans.
Most participants indicated they made the decision to stop on their own. A number of
participants reported not feeling comfortable with medication in general (“I’m not a huge
believer in long term medicated management for mental health”), and even more so during
pregnancy. Very few women in our sample expressed awareness of the risks of abruptly
discontinuing their medications, although one participant did share her fears about the potential
risks of being on medication and then subsequently weaning herself off too quickly.
A Coordinated Decision Because the COMFORT prenatal interview took place following the
participant’s visit with her VA provider for pregnancy confirmation, an opportunity for
medication review and risk discussion existed. While many participants reported such discus-
sions with their VA providers or their obstetricians, collaboration between VA providers and
obstetricians was minimally reported and most participants were unsure whether information
about mental health status was being transmitted between their VA and obstetric providers.
Those who spoke about coordinated discussions reported conferences with their OB and
mental health providers to reach a consensus on a treatment plan during pregnancy. One
participant spoke about her mental health provider collaborating with her obstetrician to the
extent of changing a medication so that both providers and the patient were comfortable with
the treatment:
 
26.9%
62.1%
23.1%
44.0%42.3%
69.0%
11.5%
40.5%
0.0%
10.0%
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50.0%
60.0%
70.0%
80.0%
No Past Depression
(n=26)
History of Depression
(n=116)
No Past Depression
(n=26)
History of Depression
(n=116)
VA Mental Health Visit VA Antidepressant Prescription
Prepregnancy
Pregnancy
Fig. 2 Mental Health Treatment Utilization*, by Pregnancy Period and Self-Reported Past Depression Diagnosis (n =
135). *Mental Health Treatment Utilization: 1+ mental health visit or 30-day antidepressant prescription in VA
Corporate Data Warehouse Electronic Health Record Data. Note: 7 of our participants (n= 1 with no past depression;
n=6 with past depression) did not have CDW data; therefore this analysis was conducted in 135 participants
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"The VA had done a great job of providing peer reviewed information saying their
decision about why they think that certain medications are safe during pregnancy. And
when that, I think professional opinion, didn’t align with what the OBGYN thought they
were very happy to basically concede and change the prescription.”
Another woman expressed satisfaction with the coordinated decision between her VA provider
and obstetrician to have her remain on her medication during pregnancy:
Fig. 3 VA Mental Health Visits* Recorded in the 280 Days Prior to Delivery, by Self-Reported Past Depression
Diagnosis, among Pregnant Veterans with Depression Symptoms (n = 135). *As recorded in the VA Corporate
DataWarehouse Electronic Health Record Data. Note: 7 of our participants (n = 1 with no past depression; n = 6
with past depression) did not have CDW data; therefore this analysis was conducted in 135 participants
Table 4 Categories, Example Codes, and Themes Identified from Qualitative Interviews with Pregnant Veterans
with Depression Symptoms (n = 42)
Category Example Codes Themes
Medication Risk Discussion
with Providers
• Communication between obstetrician
and VA provider
• Occurred with obstetrician
• Occurred with VA provider
• Personal understanding of risks
A Coordinated Decision
Use of Medications during
Pregnancy
• Continued medication use
• New medication use
Justifying Treatment
Discontinuation of Medications
during Pregnancy
• Alternative treatments
• Feelings about stopping
• Personal decision
• Provider decision
“Once I knew, I stopped”
Not Worth the Risk
Difficulties Adjusting to Life
without Medication
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“She (VA nurse practitioner) was wonderful, she actually looked up the medications because
she knew that I had gotten on the medications before I was breastfeeding. So we were very
careful about getting on it and I was postpartum from my prior pregnancy, because I had
back to back pregnancies they (VA NP and OB) both agreed about keeping me on the
medication. She (VA NP) asked me to make sure that my OB was on the same page. And he
already was so she was more than helpful. She actually went above and beyond.”
However, many participants reported not having a discussion with either their VA mental
health providers or their obstetricians, or having a discussion but remaining confused about
potential risks during pregnancy. As one woman said:
"I think it was kind of a mutual decision, I had her tell me all of the risks and she went
over all, you know, the different studies or whatever that she had pulled up and it just… I
just thought (medication) sounded dangerous and it passed through milk and things like
that, so I said I definitely wanted to get off (of) that.”
Another woman shared that her VA primary care provider was not helpful when she asked
about a mental health medication she was taking, and that she had done her own research to
decide to discontinue her medication:
“I did my research online as far as all that went, like I said, when I (tried) to talk to my
primary care…they really didn’t have anything for me as far as…medical advice…nothing.”
Not Worth the Risk Few women reported use of mental health medications during pregnancy.
Women who were hesitant to start or restart a medication explained that potential risks to the fetus
influenced their decision. Women spoke about medication being “very dangerous” and risky even
if their providers suggested a prescription and assured them the risks wereminimal. One participant
said, “I read all the manufacturing and the risks and everything and some of them said don’t take
while you’re pregnant and so I didn’t want to have any risks associated with it.” Another
participant commented, “I just don’t take them. I stopped taking them, just because I didn’t want
any developmental issues or whatever with the baby.” Additionally, one woman added:
“Yeah, she’s (provider) even mentioned like taking some antidepressants, but I told her,
you know, I’m not a big person on medicine as it is, so I don’t like to take medicine,
especially like when I’m pregnant…You know because I just don’t want to take the risk.”
One participant discussed stopping due to past experiences:
“Well, I was taking (medications) for mental health before I got pregnant, then I stopped
when I found out I was pregnant cause I don’t know, you know, how would that affect the
pregnancy, cause I already had two previous miscarriages before this baby.”
Justifying Treatment Women who spoke about taking medications during pregnancy seemed
to include reasons for justifying their use. One woman spoke about her emotions being to “the
extremes”:
“(My emotions) were either really sad, tired, angry; where I either wanted to sit in bed
all day or sit in the shower and cry all day, or if I was angry, I mean it was to the verge
of wanting to hurt others. So my OB/GYN she put me (on) the generic brand of Zoloft…
it’s helped drastically…I wasn’t on any medications whatsoever until I got pregnant.”
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Another woman who discontinued her medication during the first trimester but restarted later
in pregnancy noted potential changes to her hormones as being the cause for returning symptoms:
“I stopped taking my fluoxetine when I found out I was pregnant. And I was, it was after
I was twelve weeks that I started taking it again. I’m not sure the exact week but I
remember the doctor said that after twelve weeks it would probably be okay for me to
start taking it again. So things got a little bit rough…I don’t know if it was the hormones
that were a little more crazy but it definitely wasn’t very good.”
Difficulties Adjusting to Life without Medication Many women reported difficulties
adjusting to life without medications to manage their depression. As one woman put it, she
had to accept that her depression “is going to be an occasional problem until after I have the
kid.” Others expressed that techniques to help manage depression were not as effective during
pregnancy, or that traveling to mental health appointments had become more difficult since
becoming pregnant. One woman said that although she was grateful for the techniques she
learned in therapy, without medication “it’s just tough, it’s really tough to manage that and just,
you know, go almost a year without having any medication for it.” Very few women discussed
starting therapy or utilizing other forms of treatment in place of antidepressants. One woman
shared her hesitation about seeking care:
“Well, to be honest, all the things I’ve been through since I’ve been pregnant (has been
with) my OBGYN…I haven’t really spoke with my (VA) primary care provider or I
haven’t spoke with the therapist there…I don’t know, like, and I know this might sound
crazy, but it’s like I don’t feel too comfortable, I guess, discussing it, or I don’t know how
to bring it up, or stuff like that. I don’t know.”
Discussion
To our knowledge, this is the first study to examine mental health care and depression treatment
during pregnancy in veterans with depression symptomatology. More than half of our sample
had at least one mental health visit at the VA or received a prescription for an antidepressant in
the 280-days prior to delivery thus corresponding with the pregnancy period. However, nearly a
quarter of our sample did not receive any VA mental health care during their pregnancy. The
majority of our participants (82%) reported using antidepressants at any time prior to their
pregnancies, yet only 35% our sample filled a prescription for an antidepressant in the 280-days
prior to delivery. We expected a large proportion of our sample would discontinue use because
past research suggests women taking antidepressants prior to pregnancy discontinue use in the
prenatal period [37]. Given that treatment for depression will likely decrease further following
the birth of the child when time and childcare become barriers to treatment [10], that medication
recommendations change over the perinatal period, and that over half of perinatal depression
cases develop prior to the postpartum period [38], identifying at-risk and symptomatic women
during pregnancy is key to developing a practical treatment routine.
We found that women self-reporting a history of depression were more likely to receive
mental health care during their pregnancy, in line with previous work that showed women
veterans without a pre-pregnancy mental health diagnosis were less likely to seek outpatient
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mental healthcare during their pregnancies compared to women veterans with a pre-pregnancy
mental health diagnosis [39]. Most women who received care in the pre-pregnancy period
remained in care during pregnancy; however, women without past diagnoses may potentially
be overlooked if depression screening is not done on a routine basis. The women veterans in
our analysis who did not report a history of a depression diagnosis comprised 5% of all
pregnant veterans in our sample with a prenatal EPDS≥10, suggestive of depression symp-
tomatology [3].
The frequency of care utilization among women veterans in our sample differed consider-
ably between women with a self-reported history of depression compared to those with no self-
reported history of depression. The VA Maternity Health Care and Coordination Handbook
defines a standard of practice for maternity care coordination within VA medical facilities,
instituted to bridge the gap between existing dual VA/non-VA healthcare systems and designed
to “ensure that eligible women Veterans have access to timely prenatal care…(and) seamless
coordination of non-VA maternity care with VA care, especially in cases of women Veterans
with co-morbid conditions who may require VA care during their pregnancy” [5]. These
guidelines also recommend depression assessment, screening, counseling, and referral for care
as components of the coordination model. The guidelines specify that “VA providers must
screen all pregnant and postpartum women for depression utilizing an appropriate screening
tool, and have a system to ensure that positive screening results are followed by accurate
diagnosis, implementation of treatment, and follow-up either within the practice or through
referral” [5]. Given our quantitative findings showing that women without a history of
depression were less likely to utilize care during pregnancy, conducting early and frequent
depression screening, as well as establishing referral processes and introducing women without
a history of mental health care to the mental health resources at the VA is key for this
population. Our results indicate that veterans experiencing depression symptoms may be
lacking access to treatment, despite guidelines encouraging systems to identify these women
and establish a care routine.
Veterans in our sample qualitatively reported varying experiences with mental health care
treatment during pregnancy. While many women reported discontinuing medications after
discussions of associated risks with providers, several women reported discontinuing medica-
tions on their own, without a risk/benefit discussion with their providers. This is consistent
with other work showing that, in general, women tend to make a decision to discontinue
medications during pregnancy without the benefit of a full discussion with their providers [40].
A lack of discussion between patients and providers may also be suggestive of reluctance that
provider’s may have with discussing and prescribing psychotropic medication during preg-
nancy [7, 41], despite patients preferring their providers initiate the discussion about medica-
tion risks during pregnancy [42]. Additionally, as has been reported in similar studies, the fear
of harming the fetus often results in medication discontinuation during pregnancy [43, 44].
The stigma surrounding medication use during pregnancy is pervasive. Previous work has
found pregnant women expressing difficulties in accepting the need for a medication during
pregnancy [40] given the prevalent focus on the health of the fetus as priority over the health of
the mother [45, 46] and without recognition of the risks of untreated mental health conditions
being associated with significant risk for mother and child. Our sensitivity analyses showed a
greater number of antidepressant prescriptions in the 280-day and 300-day windows compared
to the 200-day window when looking back from the date of delivery or estimated due date; this
may be quantitative evidence that many women are discontinuing their antidepressant pre-
scriptions early in pregnancy.
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Our study is not without limitations. It is possible that women started taking an antidepressant
or seeing a mental health provider following the prenatal interview, which ranged from 4 to
39 weeks gestation in our sample, and thus would not be captured in the self-report responses.
Outside of the prenatal interview question specifically asking about antidepressant use prior to
pregnancy, our interview included broad questions regarding self-reported receipt of mental health
care rather than solely focusing on depression. Additionally, wemay have included antidepressant
prescriptions or mental health visits from the CDW data outside the actual pregnancy window,
such as prescriptions filled in very early pregnancywhichmay have been stopped upon pregnancy
confirmation. However, our sensitivity analyses using varying pregnancy windows of 200 and
300 days showed expected differences of increases in mental health visits and decreases in
antidepressant prescriptions when our pregnancy time was varied. Likewise, we were unable to
identify mental health care received during pregnancy from a non-VA provider, which may
explain our low specificity calculations. Given that most discordant cases were due towomen self-
reporting depression where it was shown absent in the EHR, this could potentially be due to
diagnoses outside of VA care (either before the veteran was receiving VA care or made by a
provider outside of the VA system). We also only included antidepressant prescriptions in our
analysis. We chose to focus on depression symptomology for this paper; however, this potentially
excludes a wide range of other mental health medications our participants may have been taking.
Finally, our findings are not generalizable to a population outside of English-speaking pregnant
veterans receiving their care within the VA medical system.
Our study also has several strengths. We enriched our survey dataset with EHR data and
examined the sensitivity and specificity of our participants self-reported history of depression
diagnoses compared to EHR records. We used both quantitative and qualitative data to enrich our
understanding of mental health care of pregnant veterans. We utilized a large, national sample to
enroll participants. Additionally, we used the EPDS which has been validated as a screening tool
for use in a pregnant population (Bergink et al., 2011). Finally, our qualitative data was obtained
from semi-structured interviews, which gave the participants flexibility in their responses.
Conclusions
Estimates of depression prior to pregnancy inwomen veterans range from 10 to 60%, suggesting a
higher likelihood of pregnant veterans developing depression compared to pregnant women in the
general population [1, 47], and depression is the most commonly diagnosed medical condition
among all women veterans ages 18–44 [48]. The US Preventive Services Task Force (USPSTF)
recently issued a draft recommendation that clinicians “provide or refer pregnant and postpartum
women who are at increased risk of perinatal depression to counseling interventions” [49]. These
recommendations are based on lack of current guidelines for preventing perinatal depression, in
light of evidence showing that counseling interventions can help improve perinatal depression
outcomes. The USPSTF recommends identifying women at-risk for perinatal depression early,
based on risk factors such as a history of depression, current depressive symptoms, and socio-
economic risk factors. Women veterans, especially given their increased risk of depression, could
benefit from preventative therapy and other interventions targeting awareness around the impor-
tance of treating depression during pregnancy. These discussions should include non-
pharmacologic and pharmacologic treatment options including balanced risk discussion address-
ing outcomes associated with untreated and `treated disease. Our study reveals that treatment and
care experiences vary among women veterans substantially. Women veterans without a history of
Psychiatric Quarterly
depression may be less likely to receive care for depression symptoms during pregnancy.
However, a majority of our sample with prenatal depression symptoms had at least one mental
health visit or an anti-depression medication fill during their pregnancy window, suggesting that
mental health care is available for women veterans when accessed.
Implications for Practice and/or Policy
Further work needs to be done to understand the extent of depression screening, medication
adherence, and treatment options among veterans in the perinatal period, especially for pregnant
women with new onset symptoms who may not have had a previous encounter with VAmental
health. Consistency in care, such as therapy for prevention of depressive symptomatology and
standards of practice for medication risk discussions, could help veterans and providers better
manage depression during pregnancy as well as encourage long-term treatment.
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